- Report
- August 2026
- 269 Pages
Global
From €5234EUR$5,850USD£4,476GBP
- Report
- November 2025
- 200 Pages
Global
From €7113EUR$7,950USD£6,083GBP
- Report
- November 2025
- 200 Pages
Global
From €7113EUR$7,950USD£6,083GBP
- Report
- October 2024
- 100 Pages
Global
From €5324EUR$5,950USD£4,553GBP
- Report
- May 2024
- 132 Pages
Global
From €2683EUR$2,999USD£2,295GBP
€3578EUR$3,999USD£3,060GBP
- Report
- May 2024
- 136 Pages
Global
From €2683EUR$2,999USD£2,295GBP
€3578EUR$3,999USD£3,060GBP
- Report
- May 2024
- 134 Pages
Global
From €2683EUR$2,999USD£2,295GBP
€3578EUR$3,999USD£3,060GBP
- Report
- December 2023
- 116 Pages
Global
From €4026EUR$4,500USD£3,443GBP
- Report
- April 2023
- 160 Pages
Global
From €4428EUR$4,949USD£3,787GBP
Amitiza is a prescription medication used to treat chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). It is a chloride channel activator that works by increasing fluid secretion in the intestines, which helps to soften stools and increase bowel movements. It is available in 8 mcg and 24 mcg capsules. Amitiza is the only FDA-approved medication for CIC and IBS-C that works by increasing fluid secretion in the intestines.
The Amitiza market is a subset of the larger gastrointestinal drugs market. It is composed of medications used to treat a variety of gastrointestinal conditions, including CIC and IBS-C. These medications are typically prescribed by gastroenterologists and other healthcare professionals.
Some companies in the Amitiza market include Allergan, Ironwood Pharmaceuticals, and Takeda Pharmaceuticals. Show Less Read more